Tocagen Inc (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

Several other equities analysts also recently weighed in on TOCA. Stifel Nicolaus began coverage on shares of Tocagen in a research note on Monday, May 15th. They issued a “buy” rating and a $24.00 price target on the stock. Leerink Swann began coverage on shares of Tocagen in a research note on Monday, May 15th. They issued a “mkt perform” rating and a $19.00 price target on the stock.

Shares of Tocagen (TOCA) traded down 5.05% during mid-day trading on Friday, hitting $12.60. 81,668 shares of the stock traded hands. The firm has a 50 day moving average of $12.04 and a 200 day moving average of $13.45. The company’s market cap is $249.59 million. Tocagen has a 12 month low of $9.68 and a 12 month high of $17.95.

Tocagen (NASDAQ:TOCA) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.04. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Equities analysts anticipate that Tocagen will post ($2.51) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/09/tocagen-inc-toca-raised-to-hold-at-zacks-investment-research.html.

Hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund purchased a new position in Tocagen during the second quarter worth about $108,000. TD Asset Management Inc. purchased a new position in Tocagen during the second quarter worth about $158,000. Schwab Charles Investment Management Inc. purchased a new position in Tocagen during the second quarter worth about $165,000. California State Teachers Retirement System purchased a new position in Tocagen during the second quarter worth about $179,000. Finally, Teachers Advisors LLC purchased a new position in Tocagen during the second quarter worth about $181,000. 37.87% of the stock is currently owned by institutional investors.

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.